- Home
- Publications
- Publication Search
- Publication Details
Title
Androgen receptor antagonists for prostate cancer therapy
Authors
Keywords
-
Journal
ENDOCRINE-RELATED CANCER
Volume 21, Issue 4, Pages T105-T118
Publisher
Bioscientifica
Online
2014-03-18
DOI
10.1530/erc-13-0545
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- ASC-J9 Suppresses Castration-Resistant Prostate Cancer Growth through Degradation of Full-length and Splice Variant Androgen Receptors
- (2015) Shinichi Yamashita et al. NEOPLASIA
- Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial†
- (2014) C. N. Sternberg et al. ANNALS OF ONCOLOGY
- First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer
- (2013) D Bianchini et al. BRITISH JOURNAL OF CANCER
- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The Discovery of Novel Human Androgen Receptor Antagonist Chemotypes Using a Combined Pharmacophore Screening Procedure
- (2013) Arnout Voet et al. ChemMedChem
- Long-term Survival and Biomarker Correlates of Tasquinimod Efficacy in a Multicenter Randomized Study of Men with Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer
- (2013) A. J. Armstrong et al. CLINICAL CANCER RESEARCH
- Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Previously Received Docetaxel: U.S. Food and Drug Administration Drug Approval Summary
- (2013) Y. M. Ning et al. CLINICAL CANCER RESEARCH
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
- (2013) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- Differential Androgen Deprivation Therapies with Anti-androgens Casodex/Bicalutamide or MDV3100/EnzalutamideversusAnti-androgen Receptor ASC-J9® Lead to PromotionversusSuppression of Prostate Cancer Metastasis
- (2013) Tzu-Hua Lin et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- An androgen receptor N-terminal domain antagonist for treating prostate cancer
- (2013) Jae-Kyung Myung et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer
- (2013) Dana E. Rathkopf et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the Binding Function 3 (BF3) Site of the Androgen Receptor Through Virtual Screening. 2. Development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole Derivatives
- (2013) Ravi Shashi Nayana Munuganti et al. JOURNAL OF MEDICINAL CHEMISTRY
- Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer
- (2013) Javier Guerrero et al. PROSTATE
- Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling
- (2013) T-H Lin et al. Cell Death & Disease
- An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
- (2013) M. Korpal et al. Cancer Discovery
- A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
- (2013) J. D. Joseph et al. Cancer Discovery
- Overcoming mutation-based resistance to antiandrogens with rational drug design
- (2013) Minna D Balbas et al. eLife
- Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer
- (2013) James T. Dalton et al. Current Opinion in Supportive and Palliative Care
- ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
- (2012) N. J. Clegg et al. CANCER RESEARCH
- Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100
- (2012) J. Richards et al. CANCER RESEARCH
- The Efficacy and Safety of Degarelix, a GnRH Antagonist: A 12-month, Multicentre, Randomized, Maintenance Dose-finding Phase II Study in Japanese Patients with Prostate Cancer
- (2012) S. Ozono et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: Effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys
- (2012) Masuo Yamaoka et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Identification and Characterization of MEL-3, a Novel AR Antagonist That Suppresses Prostate Cancer Cell Growth
- (2012) Christine Helsen et al. MOLECULAR CANCER THERAPEUTICS
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanism of Androgen Receptor Antagonism by Bicalutamide in the Treatment of Prostate Cancer
- (2011) D. J. Osguthorpe et al. BIOCHEMISTRY
- New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist
- (2011) Marc B. Garnick et al. BJU INTERNATIONAL
- Targeting Continued Androgen Receptor Signaling in Prostate Cancer
- (2011) C. Massard et al. CLINICAL CANCER RESEARCH
- Structural Basis for Agonism and Antagonism for a Set of Chemically Related Progesterone Receptor Modulators
- (2011) Scott J. Lusher et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Targeting the Binding Function 3 (BF3) Site of the Human Androgen Receptor through Virtual Screening.
- (2011) Nathan A. Lack et al. JOURNAL OF MEDICINAL CHEMISTRY
- A Phase III Extension Trial With a 1-Arm Crossover From Leuprolide to Degarelix: Comparison of Gonadotropin-Releasing Hormone Agonist and Antagonist Effect on Prostate Cancer
- (2011) E. David Crawford et al. JOURNAL OF UROLOGY
- Structural basis for nuclear hormone receptor DNA binding
- (2011) Christine Helsen et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Reduced Expression of the Androgen Receptor by Third Generation of Antisense Shows Antitumor Activity in Models of Prostate Cancer
- (2011) Y. Zhang et al. MOLECULAR CANCER THERAPEUTICS
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Modulation of Androgen Receptor Signaling in Hormonal Therapy-Resistant Prostate Cancer Cell Lines
- (2011) Rute B. Marques et al. PLoS One
- Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): Head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model
- (2011) Robert D. Bruno et al. STEROIDS
- Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor
- (2010) Raymond J. Andersen et al. CANCER CELL
- Discovery and Mechanistic Characterization of a Novel Selective Nuclear Androgen Receptor Exporter for the Treatment of Prostate Cancer
- (2010) R. Narayanan et al. CANCER RESEARCH
- Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk
- (2010) Glenn N. Levine et al. CIRCULATION
- EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease
- (2010) Axel Heidenreich et al. EUROPEAN UROLOGY
- Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer
- (2010) Daniel C. Danila et al. JOURNAL OF CLINICAL ONCOLOGY
- Structure−Activity Relationship for Thiohydantoin Androgen Receptor Antagonists for Castration-Resistant Prostate Cancer (CRPC)
- (2010) Michael E. Jung et al. JOURNAL OF MEDICINAL CHEMISTRY
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- The Rules of DNA Recognition by the Androgen Receptor
- (2010) Sarah Denayer et al. MOLECULAR ENDOCRINOLOGY
- Drug safety is a barrier to the discovery and development of new androgen receptor antagonists
- (2010) William R. Foster et al. PROSTATE
- Do infantile testicular germ cell tumors histogenetically develop from conventional intratubular germ cell neoplasia?
- (2010) Sven Gunia et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer
- (2009) Celestia S. Higano et al. CANCER
- Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer
- (2009) Qianben Wang et al. CELL
- Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
- (2009) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial
- (2009) Jacques Irani et al. LANCET ONCOLOGY
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth
- (2008) R. B. Montgomery et al. CANCER RESEARCH
- Degarelix: A Novel Gonadotropin-Releasing Hormone (GnRH) Receptor Blocker—Results from a 1-yr, Multicentre, Randomised, Phase 2 Dosage-Finding Study in the Treatment of Prostate Cancer
- (2008) Hendrik Van Poppel et al. EUROPEAN UROLOGY
- Molecular basis of agonicity and antagonicity in the androgen receptor studied by molecular dynamics simulations
- (2008) William H. Bisson et al. JOURNAL OF MOLECULAR GRAPHICS & MODELLING
- Structural basis for nuclear receptor corepressor recruitment by antagonist-liganded androgen receptor
- (2008) Myles C. Hodgson et al. MOLECULAR CANCER THERAPEUTICS
- Androgen receptor inactivation contributes to antitumor efficacy of 17 -hydroxylase/17,20-lyase inhibitor 3 -hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer
- (2008) T. Vasaitis et al. MOLECULAR CANCER THERAPEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started